Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend "most favored nation" (MFN) pricing to Medicaid, Pfizer bought itself a three-year tariff reprieve and plenty of goodwill. But the ripple effects could redraw the profit map for insurers, pharmacies, and rival drugmakers.
- Track PFE stock here.
